Anup Kasi, MD MPH
Dr. Anup Kasi, an accomplished GI Medical Oncologist and Associate Professor of Medicine at the University of Kansas Cancer Center., where he serves as the Vice Chair for the GI disease working group. He also holds the position of Medical Director of the solid tumor molecular tumor board, utilizing his knowledge in molecular oncology for enhanced patient care.
Dr. Kasi obtained his medical degree from Bangalore Medical College and Research Institute, India, and holds a Master of Public Health degree from the University of Texas School of Public Health, with his thesis project completed at MD Anderson Cancer Center. He completed his residency in Internal Medicine and specialized in Hematology-Oncology and GI Medical Oncology fellowship at the University of Kansas Cancer Center. Additionally, he has completed a prestigious Global Clinical Scholar Research Training program at Harvard University.
Dr. Kasi's contributions extend beyond his institution, as he has actively served on the National Pancreas Task Force of the NCI Gastrointestinal Steering Committee. He has a strong background in clinical trial research, with numerous publications, awards, and presentations to his name, highlighting his leadership and expertise in clinical research.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:IpsenTopic:consultingDate added:08/10/2023Date updated:08/10/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Cardinal HealthTopic:HonorariaDate added:08/10/2023Date updated:08/10/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:GSKTopic:Research Funding to InstitutionDate added:08/10/2023Date updated:08/10/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:AstellasTopic:Research Funding to InstitutionDate added:08/10/2023Date updated:08/10/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:LisataTopic:Research Funding to InstitutionDate added:08/10/2023Date updated:08/10/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:AbilityTopic:Research Funding to InstitutionDate added:08/10/2023Date updated:08/10/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:NovocureTopic:Research Funding to InstitutionDate added:08/10/2023Date updated:08/10/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:CardiffTopic:Research Funding to InstitutionDate added:08/10/2023Date updated:08/10/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:Panavance TherapeuticsTopic:Research Funding to InstitutionDate added:08/10/2023Date updated:08/10/2023